Cell_NN Cycle_NP Regulation_NP by_IN Kaposi_NP 's_POS Sarcoma-Associated_NP Herpesvirus_NP K-bZIP_NP :_: Direct_NP Interaction_NP with_IN Cyclin-CDK2_NP and_CC Induction_NP of_IN G1_NP Growth_NP Arrest_NP In_IN order_NN to_TO cope_VB with_IN hostile_JJ host_NN environments_NNS ,_, many_JJ viruses_NNS have_VBP developed_VBN strategies_NNS to_TO perturb_VB the_DT cellular_JJ machinery_NN to_TO suit_VB their_PP$ replication_NN needs_NNS ._SENT Some_DT herpesvirus_NN genes_NNS protect_VBP cells_NNS from_IN undergoing_VBG apoptosis_NN to_TO prolong_VB the_DT lives_NNS of_IN infected_JJ cells_NNS ,_, while_IN others_NNS ,_, such_JJ as_IN Epstein-Barr_NP virus_NN Zta_NP ,_, slow_VB down_RP the_DT G1/S_NP transition_NN phase_NN to_TO allow_VB ample_JJ opportunity_NN for_IN transcription_NN and_CC translation_NN of_IN viral_JJ genes_NNS before_IN the_DT onset_NN of_IN cellular_JJ genomic_JJ replication_NN ._SENT In_IN this_DT study_NN ,_, we_PP investigated_VBD whether_IN Kaposi_NP 's_POS sarcoma-associated_JJ herpesvirus_NN (_( KSHV_NP )_) K-bZIP_NP ,_, a_DT homologue_NN of_IN the_DT Epstein-Barr_NP virus_NN transcription_NN factor_NN BZLF1_NP (_( Zta_NP )_) ,_, plays_VBZ a_DT role_NN in_IN cell_NN cycle_NN regulation_NN ._SENT Here_RB we_PP show_VBP that_IN K-bZIP_NP physically_RB associates_NNS with_IN cyclin-CDK2_NN and_CC downmodulates_VBZ its_PP$ kinase_NN activity_NN ._SENT The_DT association_NN can_MD be_VB detected_VBN in_IN the_DT natural_JJ environment_NN of_IN KSHV-infected_NP cells_NNS without_IN artificial_JJ overexpression_NN of_IN either_DT component_NN ._SENT With_IN purified_VBN protein_NN ,_, it_PP can_MD be_VB shown_VBN that_IN the_DT interaction_NN between_IN K-bZIP_NP and_CC cyclin-CDK2_NN is_VBZ direct_JJ and_CC that_IN K-bZIP_NP alone_RB is_VBZ sufficient_JJ to_TO inhibit_VB CDK2_JJ activity_NN ._SENT The_DT interacting_VBG domain_NN of_IN K-bZIP_NP has_VBZ been_VBN mapped_VBN to_TO the_DT basic_JJ region_NN ._SENT The_DT result_NN of_IN these_DT associations_NNS is_VBZ a_DT prolonged_JJ G1_JJ phase_NN ,_, accompanied_VBN by_IN the_DT induction_NN of_IN p21_JJ and_CC p27_JJ in_IN a_DT naturally_RB infected_JJ B-cell_NN line_NN ._SENT Thus_RB ,_, in_IN addition_NN to_TO the_DT previously_RB described_VBN transcription_NN and_CC genome_NN replication_NN functions_NNS ,_, a_DT new_JJ role_NN of_IN K-bZIP_NP in_IN KSHV_NP replication_NN is_VBZ identified_VBN in_IN this_DT report_NN ._SENT Herpesvirus_NN replication_NN is_VBZ often_RB broken_VBN down_RP into_IN early_JJ ,_, delayed-early_RB ,_, late_RB ,_, and_CC latent_JJ phases_NNS ._SENT The_DT cellular_JJ environment_NN required_VBN for_IN each_DT phase_NN is_VBZ unique_JJ ,_, and_CC a_DT number_NN of_IN viral_JJ genes_NNS have_VBP evolved_VBN to_TO interact_VB with_IN host_NN factors_NNS to_TO create_VB a_DT more_RBR favorable_JJ environment_NN for_IN viral_JJ replication_NN ._SENT Regulation_NN or_CC deregulation_NN of_IN the_DT cell_NN cycle_NN is_VBZ one_CD strategy_NN often_RB used_VBN by_IN viruses_NNS to_TO alter_VB the_DT cellular_JJ environment_NN ._SENT In_IN the_DT literature_NN ,_, there_EX is_VBZ a_DT preponderance_NN of_IN evidence_NN showing_VBG that_DT viral_JJ gene_NN products_NNS interact_VBP with_IN cell_NN cycle_NN proteins_NNS such_JJ as_IN cyclins_NNS and_CC CDKs_NNS or_CC their_PP$ regulators_NNS such_JJ as_IN p53_NN and_CC retinoblastoma_NN protein_NN ._SENT Some_DT of_IN these_DT interactions_NNS lead_VBP to_TO accelerated_VBN cell_NN cycle_NN progression_NN and_CC cellular_JJ proliferation_NN ,_, in_IN some_DT cases_NNS contributing_VBG to_TO the_DT transformation_NN of_IN target_NN cells_NNS ._SENT Other_JJ herpesvirus_NN gene_NN products_NNS delay_VBP cell_NN cycle_NN progression_NN and_CC transiently_RB arrest_VB the_DT infected_JJ cells_NNS at_IN the_DT G1_JJ stage_NN ._SENT This_DT usually_RB occurs_VBZ among_IN the_DT first_JJ stages_NNS of_IN the_DT viral_JJ life_NN cycle_NN and_CC involves_VBZ immediate-early_JJ and/or_CC early_JJ gene_NN products_NNS ,_, such_JJ as_IN ICP0_NP and_CC ICP27_JJ of_IN herpes_NN simplex_JJ virus_NN ,_, IE2_NP and_CC UL69_NP of_IN cytomegalovirus_NN ,_, and_CC Zta_NP of_IN Epstein-Barr_NP virus_NN (_( EBV_NP )_) ._SENT It_PP was_VBD postulated_VBN that_IN lengthening_VBG the_DT G1_JJ phase_NN would_MD give_VB additional_JJ time_NN for_IN the_DT virus_NN to_TO complete_VB transcription_NN and_CC translation_NN of_IN early_JJ genes_NNS and_CC for_IN viral_JJ DNA_NN replication_NN to_TO occur_VB before_IN the_DT onset_NN of_IN competing_VBG cellular_JJ genomic_JJ replication_NN (_( see_VB reference_NN for_IN a_DT review_NN )_) ._SENT The_DT molecular_JJ mechanisms_NNS by_IN which_WDT viral_JJ gene_NN products_NNS interfere_VBP with_IN G1_NP to_TO S_NP progression_NN differ_VBP from_IN virus_NN to_TO virus_NN ._SENT Both_DT EBV_NP Zta_NP and_CC cytomegalovirus_NN IE2_NN are_VBP known_VBN to_TO bind_VB p53_NN and_CC stabilize_VB it_PP ._SENT On_IN the_DT other_JJ hand_NN ,_, cytomegalovirus_NN IE2_NN also_RB binds_VBZ retinoblastoma_NN protein_NN and_CC releases_VBZ E2F_NP ,_, which_WDT transcriptionally_RB activates_VBZ cyclin_NN E_NN gene_NN expression_NN ._SENT By_IN these_DT means_NN ,_, cytomegalovirus_NN blocks_NNS cellular_JJ DNA_NP replication_NN while_NN at_IN the_DT same_JJ time_NN it_PP activates_VBZ certain_JJ cell_NN cycle_NN pathways_NNS to_TO provide_VB a_DT more_RBR suitable_JJ environment_NN for_IN viral_JJ DNA_NN replication_NN ._SENT The_DT overall_JJ consequence_NN of_IN these_DT interactions_NNS is_VBZ to_TO slow_VB down_RP the_DT G1_NP to_TO S_NP transition_NN ._SENT Kaposi_NP 's_POS sarcoma-associated_JJ herpesvirus_NN (_( KSHV_NP )_) ,_, also_RB known_VBN as_IN human_JJ herpesvirus_NP 8_CD ,_, is_VBZ a_DT member_NN of_IN the_DT gammaherpesvirus_NN family_NN ,_, which_WDT includes_VBZ EBV_NP and_CC herpesvirus_NN saimiri_NNS ._SENT KSHV_NP infection_NN is_VBZ associated_VBN with_IN all_DT types_NNS of_IN Kaposi_NP 's_POS sarcoma_NN ,_, including_VBG AIDS-associated_JJ ,_, endemic_JJ ,_, and_CC renal_JJ transplant-related_JJ Kaposi_NP 's_POS sarcoma_NN ._SENT It_PP has_VBZ also_RB been_VBN implicated_VBN in_IN B-cell_NN lymphoproliferative_JJ diseases_NNS such_JJ as_IN primary_JJ effusion_NN lymphoma_NN and_CC multicentric_JJ Castleman_NP 's_POS disease_NN ._SENT Like_IN other_JJ herpesviruses_NNS ,_, KSHV_NP encodes_VBZ both_DT latent_JJ and_CC lytic_JJ genes_NNS ._SENT The_DT latent_JJ genes_NNS are_VBP thought_VBN to_TO be_VB primarily_RB responsible_JJ for_IN the_DT maintenance_NN of_IN latency_NN and_CC directly_RB involved_VBN in_IN cell_NN transformation_NN ._SENT The_DT lytic_JJ genes_NNS are_VBP involved_VBN either_RB directly_RB in_IN viral_JJ replication_NN (_( genome_NN replication_NN ,_, transcription_NN ,_, etc._FW )_) or_CC in_IN providing_VBG a_DT cellular_JJ environment_NN conducive_JJ for_IN viral_JJ replication_NN (_( e.g._FW ,_, B-cell_NN activation_NN ,_, immune_JJ modulation_NN of_IN host_NN response_NN ,_, target_NN cell_NN recruitment_NN )_) or_CC both_DT ._SENT Products_NNS from_IN both_DT latent_JJ and_CC lytic_JJ genes_NNS have_VBP been_VBN shown_VBN to_TO interact_VB with_IN cell_NN cycle_NN proteins_NNS or_CC their_PP$ regulators_NNS ._SENT Perhaps_RB the_DT best_RBS known_JJ is_VBZ v-cyclin_NN ,_, which_WDT directly_RB interacts_VBZ with_IN and_CC activates_VBZ cellular_JJ CDK6_NP ,_, thereby_RB accelerating_VBG cell_NN cycle_NN progression_NN ._SENT Other_JJ viral_JJ gene_NN products_NNS such_JJ as_IN latency-associated_JJ nuclear_JJ antigen_NN (_( LANA_NP )_) interact_VBP with_IN the_DT cell_NN cycle_NN regulator_NN p53_NN and_CC thus_RB can_MD potentially_RB perturb_VB both_CC the_DT cell_NN cycle_NN and_CC apoptosis_NN programs_NNS ._SENT Previously_RB ,_, we_PP reported_VBD the_DT identification_NN of_IN an_DT early_JJ KSHV_NP gene_NN product_NN ,_, K-bZIP_NP ,_, which_WDT is_VBZ the_DT positional_JJ and_CC structural_JJ homolog_NN of_IN EBV_NP Zta_NP ._SENT We_PP show_VBP here_RB that_IN K-bZIP_NP interacts_VBZ directly_RB with_IN cyclin-CDK2_NN and_CC downmodulates_VBZ the_DT kinase_NN activity_NN of_IN CDK2_NP ,_, resulting_VBG in_IN G1_JJ growth_NN arrest_NN of_IN the_DT host_NN cells_NNS ._SENT The_DT association_NN of_IN K-bZIP_NP and_CC CDK2_NP can_MD be_VB detected_VBN in_IN the_DT naturally_RB infected_JJ BCBL-1_NP line_NN ,_, and_CC the_DT expression_NN of_IN K-bZIP_NP but_CC not_RB of_IN a_DT mutant_NN lacking_VBG the_DT interaction_NN domain_NN results_NNS in_IN slower_JJR growth_NN of_IN cells_NNS ._SENT This_DT growth_NN arrest_NN is_VBZ accompanied_VBN by_IN the_DT increased_VBN expression_NN of_IN p21_JJ and_CC p27_JJ ._SENT Our_PP$ results_NNS suggest_VBP that_IN K-bZIP_NP ,_, in_IN addition_NN to_TO being_VBG a_DT transcriptional_JJ regulator_NN ,_, is_VBZ also_RB directly_RB involved_VBN in_IN cell_NN cycle_NN regulation_NN ._SENT Plasmids_NNS ._SENT |_SYM Plasmids_NNS encoding_VBG the_DT full-length_JJ K-bZIP_NP (_( K-bZIP/wt_NP ,_, residues_NNS 1_CD to_TO 273_CD )_) were_VBD constructed_VBN in_IN pcDNA3.1_JJ (_( Invitrogen_NP )_) ._SENT Cloning_VBG introduced_VBN a_DT CpoI_NP site_NN and_CC either_RB a_DT hemagglutinin_NN (_( HA_NP )_) tag_NN ,_, a_DT Flag_NP tag_NN ,_, or_CC a_DT T7_JJ tag_NN to_TO the_DT N_NP terminus_NN as_RB described_VBD previously_RB ._SENT The_DT resulting_VBG plasmids_NNS were_VBD denoted_VBN pHA-K-bZIP_NN ,_, pFlag-K-bZIP_NN ,_, and_CC pT7-K-bZIP_NN ,_, respectively_RB ._SENT A_DT natural_JJ spliced_VBN variant_NN of_IN K-bZIP_NP ,_, K-bZIPDeltaLZ_NP ,_, which_WDT carries_VBZ a_DT deletion_NN of_IN the_DT leucine_NN zipper_NN region_NN ,_, was_VBD inserted_VBN in-frame_JJ 3_CD '_'' of_IN the_DT Flag_NP tag_NN sequence_NN of_IN modified_JJ pcDNA3.1_NN as_RB described_VBD previously_RB ._SENT The_DT resulting_VBG plasmid_NN was_VBD denoted_VBN pFlag-K-bZIPDeltaLZ_NN ._SENT An_DT expression_NN plasmid_NN with_IN a_DT deletion_NN of_IN the_DT K-bZIP_NP basic_JJ region_NN (_( BR_NP )_) (_( residues_NNS 123_CD to_TO 189_CD )_) (_( pFlag-K-bZIPDeltaBR_NN )_) was_VBD constructed_VBN as_IN described_VBN previously_RB ._SENT Deletion_NN fragments_NNS of_IN K-bZIP_NP were_VBD amplified_VBN by_IN PCR_NP with_IN Pfu_NP Turbo_NP (_( Stratagene_NP )_) with_IN primers_NNS as_RB described_VBD previously_RB and_CC then_RB cloned_VBN into_IN a_DT modified_JJ pGEX4T-2_NN (_( Amersham-Pharmacia_NP )_) ,_, which_WDT introduced_VBD a_DT CpoI_NP site_NN to_TO produce_VB glutathione_NN S-transferase_NP (_( GST_NP )_) fusion_NN proteins_NNS ._SENT To_TO prepare_VB additional_JJ K-bZIP_NP deletion_NN mutants_NNS in_IN this_DT study_NN ,_, K-bZIP_NP deletion_NN fragments_NNS were_VBD amplified_VBN with_IN the_DT following_VBG primer_NN pairs_NNS (_( italics_NNS designate_VBP CpoI_NP sites_NNS and_CC capital_NN letters_NNS denote_VBP the_DT viral_JJ sequence_NN )_) :_: K-bZIP_NP 107F_NP (_( 5'-aac_JJ ggt_NN ccg_NN CTC_NP TCT_NP CAC_NP ACA_NP CCA_NP CCA_NP AGA-3_NP '_'' )_) and_CC K-bZIP_NP 157R_NP (_( 5'-aac_NP gga_NP ccg_NN CTT_NP AAC_NP TAC_NP AGA_NP CGC_NP AGG_NP CAC-3_NP '_POS )_) ,_, and_CC K-bZIP_NP 158F_NP (_( 5'-aac_JJ ggt_NN ccg_NN GCC_NP GAA_NP GTA_NP TGT_NP GAT_NP CAG_NP TC-3_NP '_'' )_) and_CC K-bZIP_NP 208R_NP (_( 5'-aac_NP gga_NP ccg_NN CTT_NP ATG_NP TGC_NP CTC_NP CAA_NP TCT_NP CGC-3_NP '_'' )_) ._SENT Amplified_VBN fragments_NNS were_VBD then_RB digested_VBN with_IN CpoI_NP (_( Fermentas_NP )_) and_CC inserted_VBN in_IN frame_NN downstream_JJ of_IN the_DT GST_JJ coding_VBG sequence_NN ._SENT Expression_NN plasmids_NNS for_IN CDK2_NP ,_, cyclin_NP A_NP ,_, and_CC cyclin_NN E_NN were_VBD a_DT generous_JJ gift_NN from_IN D._NP J._NP Templeton_NP (_( Case_NP Western_NP Reserve_NP University_NP )_) ._SENT Cell_NN culture_NN ,_, transient_JJ transfection_NN ,_, establishment_NN of_IN K-bZIP_NP stable_JJ transfectants_NNS ,_, and_CC growth_NN rate_NN analysis_NN ._SENT |_SYM Epithelial_NP human_JJ embryonic_JJ kidney_NN cell_NN lines_NNS 293_CD and_CC 293T_JJ ,_, as_RB well_RB as_IN a_DT cervical_JJ carcinoma_NN cell_NN line_NN ,_, HeLa_NP cells_NNS ,_, were_VBD grown_VBN in_IN monolayer_NN cultures_NNS in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN (_( DMEM_NP )_) supplemented_VBD with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN in_IN the_DT presence_NN of_IN 5_CD %_NN CO2_NP ._SENT To_TO establish_VB stable_JJ expression_NN of_IN Flag-control_NP ,_, Flag-K-bZIP_NP ,_, Flag-K-bZIPDeltaBR_NP ,_, and_CC Flag-K-bZIPDeltaLZ_NP ,_, 293_CD cells_NNS were_VBD transfected_VBN with_IN 10_CD mug_NN of_IN each_DT expression_NN plasmid_NN ,_, which_WDT contained_VBD the_DT G418_NP resistance_NN gene_NN ._SENT After_IN 2_CD to_TO 3_CD weeks_NNS of_IN selection_NN with_IN medium_NN containing_VBG 400_CD mug_NN of_IN G418_NP per_IN ml_NP (_( Gibco-BRL_NP )_) ,_, individual_JJ G418-resistant_NP colonies_NNS were_VBD cloned_VBN and_CC tested_VBN for_IN the_DT expression_NN of_IN K-bZIP_NP and_CC its_PP$ mutants_NNS by_IN Western_JJ blot_NN analysis_NN ._SENT These_DT stable_JJ cell_NN lines_NNS were_VBD grown_VBN at_IN 37C_JJ in_IN DMEM_NP supplemented_VBD with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN and_CC 200_CD mug_NN of_IN G418_NP per_IN ml_NN in_IN the_DT presence_NN of_IN 5_CD %_NN CO2_NP ._SENT To_TO establish_VB BCBL-1_JJ cells_NNS stably_RB expressing_VBG HA-K-bZIP_NP ,_, cells_NNS were_VBD transfected_VBN with_IN 20_CD mug_NN of_IN pHA-K-bZIP_NN ,_, which_WDT contains_VBZ a_DT G418_NP resistance_NN gene_NN ._SENT Stable_JJ cells_NNS were_VBD collected_VBN as_IN described_VBN previously_RB ._SENT These_DT stable_JJ cell_NN pools_NNS were_VBD maintained_VBN in_IN RPMI_NP 1640_CD supplemented_VBD with_IN 15_CD %_NN fetal_JJ bovine_JJ serum_NN and_CC 200_CD mug_NN of_IN G418_NP per_IN ml_NN in_IN the_DT presence_NN of_IN 5_CD %_NN CO2_NN ._SENT Both_DT viral_JJ lytic_JJ replication_NN and_CC HA-K-bZIP_NN expression_NN were_VBD induced_VBN by_IN treatment_NN of_IN log-phase_JJ HA-K-bZIP_NP stable_JJ BCBL-1_NP cells_NNS with_IN tetradecanoyl_NN phorbol_NN acetate_NN (_( TPA_NP )_) (_( 20_CD ng/ml_NNS ;_: Sigma_NP )_) ._SENT For_IN determination_NN of_IN growth_NN rate_NN ,_, 5_CD x_SYM 104_CD cells_NNS from_IN each_DT of_IN the_DT cell_NN clones_NNS were_VBD seeded_VBN in_IN 60-mm_JJ plates_NNS ._SENT Cell_NN numbers_NNS were_VBD counted_VBN at_IN the_DT indicated_JJ time_NN postseeding_NN ._SENT Triplicate_JJ plates_NNS were_VBD seeded_VBN for_IN each_DT cell_NN clone_NN ._SENT Cell_NN cycle_NN analysis_NN ._SENT |_SYM For_IN cell_NN cycle_NN analysis_NN ;_: BCBL-1_NP ,_, GA10_NP ,_, and_CC BCP-1_NP cells_NNS were_VBD collected_VBN ,_, washed_VBN once_RB with_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) ,_, suspended_VBN in_IN 0.5_CD ml_NN of_IN cold_JJ (_( 4C_JJ )_) PBS-0.1_JJ %_NN glucose_NN ,_, fixed_VBN with_IN 5_CD ml_NN of_IN ice-cold_JJ 70_CD %_NN ethanol_NN for_IN at_IN least_JJS 45_CD min_NN at_IN 4C_JJ ,_, washed_VBN with_IN PBS_NP ,_, and_CC treated_VBN with_IN RNase_NP A_NP (_( 0.1_CD mg/ml_NN )_) in_IN a_DT propidium_NN iodide_NN (_( 69_CD mM_NNS ;_: Sigma)-sodium_NN citrate_NN (_( 38_CD mM_NP )_) solution_NN ._SENT Cell_NN cycle_NN analysis_NN was_VBD performed_VBN by_IN fluorescence-activated_JJ cell_NN sorting_VBG (_( FACScan_NP ;_: Becton_NP Dickinson_NP )_) with_IN the_DT ModFit_NP LT_NP version_NN 2.0_CD software_NN (_( Verity_NP Software_NP House_NP Inc._NP )_) ._SENT Immunoprecipitation_NN and_CC immunoblot_NN analyses_NNS ._SENT |_SYM BCBL-1_NP cells_NNS were_VBD rinsed_VBN in_IN ice-cold_JJ PBS_NP ,_, and_CC 107_CD cells_NNS were_VBD lysed_VBN in_IN EBC_NP lysis_NN buffer_NN (_( 50_CD mM_NP Tris-HCl_NP [_SYM pH_NN 7.5_CD ]_SYM ,_, 120_CD mM_NP NaCl_NP ,_, 0.5_CD %_NN NP-40_NP ,_, 50_CD mM_NP NaF_NP ,_, 200_CD muM_NN Na2VO4_NP ,_, 1_CD mM_NP phenylmethylsulfonyl_NN fluoride_NN )_) supplemented_VBN with_IN a_DT protease_NN inhibitor_NN cocktail_NN (_( Roche_NP )_) ._SENT After_IN centrifugation_NN (_( 15,000_CD x_SYM g_NN for_IN 10_CD min_NN at_IN 4C_JJ )_) ,_, 20_CD mul_NN of_IN protein_NN A-_NN and_CC protein_NN G-Sepharose_NN beads_NNS (_( Upstate_NP )_) were_VBD added_VBN to_TO the_DT supernatants_NNS and_CC incubated_VBD overnight_RB at_IN 4C_JJ ._SENT Then_RB 500_CD mug_NN of_IN each_DT of_IN the_DT cleared_VBN supernatants_NNS was_VBD reacted_VBN with_IN 3_CD mug_NN of_IN anti-CDK2_NP (_( SC-163_NP ;_: Santa_NP Cruz_NP )_) ,_, anti-cyclin_NP A_NP (_( SC-751_NP ;_: Santa_NP Cruz_NP )_) ,_, anti-cyclin_NP E_NP (_( SC-481_NP ;_: Santa_NP Cruz_NP )_) ,_, anti-cyclin_NP D_NP (_( Upstate_NP )_) ,_, anti-CDK4_NP (_( SC-260-G_NP ;_: Santa_NP Cruz_NP )_) ,_, anti-p53_NP (_( SC-126_NP ;_: Santa_NP Cruz_NP )_) ,_, anti-p107_JJ (_( SC-318_NP ;_: Santa_NP Cruz_NP )_) ,_, anti-cdc2_NP (_( SC-54_NP ;_: Santa_NP Cruz_NP )_) ,_, anti-p21_NP (_( SC-397_NP ;_: Santa_NP Cruz_NP )_) ,_, anti-p27_JJ (_( SC-1641_NP ;_: Santa_NP Cruz_NP )_) ,_, antitubulin_NP (_( SC-8035_NP ;_: Santa_NP Cruz_NP )_) ,_, or_CC anti-HA_NP (_( Babco_NP )_) for_IN 3_CD h_NN to_TO overnight_JJ at_IN 4C_JJ with_IN gentle_JJ rotation_NN ._SENT The_DT immune_JJ complex_NN was_VBD captured_VBN by_IN the_DT addition_NN 20_CD mul_NN of_IN a_DT protein_NN A-_NN and_CC protein_NN G-Sepharose_NN bead_NN mixture_NN and_CC rocked_VBN for_IN an_DT additional_JJ 2_CD h_NN at_IN 4C_JJ ._SENT Beads_NNS were_VBD washed_VBN four_CD times_NNS with_IN EBC_NP buffer_NN and_CC then_RB boiled_VBD for_IN 5_CD min_NN in_IN 20_CD mul_NN of_IN 2x_JJ sodium_NN dodecyl_NN sulfate_NN (_( SDS_NP )_) sample_NN buffer_NN (_( 125_CD mM_NP Tris-HCl_NP [_SYM pH_NN 6.8_CD ]_SYM ,_, 4_CD %_NN SDS_NP ,_, 10_CD %_NN 2-mercaptoethanol_JJ ,_, 20_CD %_NN glycerol_NN ,_, 0.6_CD %_NN bromophenol_NN blue_NN )_) ._SENT 293T_JJ cells_NNS were_VBD cotransfected_VBN with_IN 2_CD mug_NN of_IN pT7-K-bZIP_NN and_CC 3_CD mug_NN of_IN pFlag-CDK2_JJ or_CC pFlag-empty_JJ expression_NN plasmids_NNS with_IN FuGene_NP 6_CD (_( Roche_NP )_) according_VBG to_TO the_DT supplier_NN 's_POS recommendations_NNS ._SENT The_DT cells_NNS were_VBD harvested_VBN 48_CD h_NN after_IN transfection_NN and_CC lysed_VBN in_IN EBC_NP buffer_NN ._SENT Then_RB 500_CD mug_NN of_IN cell_NN lysates_NNS was_VBD immunoprecipitated_VBN with_IN the_DT addition_NN of_IN 25_CD mul_NN of_IN anti-Flag_NP antibody-conjugated_JJ agarose_NN (_( Sigma_NP )_) ._SENT The_DT beads_NNS were_VBD washed_VBN four_CD times_NNS with_IN EBC_NP buffer_NN and_CC then_RB boiled_VBD for_IN 5_CD min_NN in_IN 20_CD mul_NN of_IN 2x_NP SDS_NP sample_NN buffer_NN ._SENT Protein_NN samples_NNS from_IN total_JJ cell_NN lysates_NNS (_( 50_CD mug/lane_NN )_) or_CC immunoprecipitates_NNS were_VBD subjected_VBN to_TO SDS-10_NP %_NN polyacrylamide_NN gel_NN electrophoresis_NN (_( PAGE_NP )_) and_CC then_RB transferred_VBN to_TO a_DT polyvinylidene_JJ difluoride_NN membrane_NN (_( Biotechnology_NP Systems_NPS )_) with_IN a_DT semidry_JJ transfer_NN apparatus_NN (_( Amersham_NP Pharmacia_NP )_) ._SENT After_IN blocking_VBG for_IN 1_CD h_NN at_IN room_NN temperature_NN with_IN 5_CD %_NN skim_NN milk_NN in_IN TBST_NP (_( 20_CD mM_NP Tris-HCl_NP [_SYM pH_NN 7.5_CD ]_SYM ,_, 137_CD mM_NP NaCl_NP ,_, 0.05_CD %_NN Tween_NP 20_CD )_) ,_, the_DT membranes_NNS were_VBD incubated_VBN with_IN primary_JJ antibodies_NNS for_IN 2_CD h_NN at_IN room_NN temperature_NN ._SENT The_DT membranes_NNS were_VBD subsequently_RB washed_VBN with_IN TBST_NP three_CD times_NNS for_IN 10_CD min_NN each_DT at_IN room_NN temperature_NN and_CC then_RB incubated_VBN with_IN horseradish_NN peroxidase-conjugated_JJ antibodies_NNS for_IN 1_CD h_NN at_IN room_NN temperature_NN ._SENT The_DT membranes_NNS were_VBD then_RB washed_VBN three_CD times_NNS with_IN TBST_NP and_CC visualized_VBN with_IN enhanced_JJ chemiluminescence_NN reagents_NNS (_( Amersham-Pharmacia_NP )_) ._SENT Final_JJ dilutions_NNS of_IN the_DT first_JJ antibodies_NNS for_IN immunoblotting_NN were_VBD 1:4,000_CD for_IN the_DT rabbit_NN anti-K-bZIP_NN antibody_NN ,_, 1:3,000_CD for_IN the_DT anti-T7_JJ antibody_NN (_( Novagen_NP )_) ,_, 1_CD mug_NN of_IN antiactin_NP (_( SC-1615_NP ;_: Santa_NP Cruz_NP )_) ,_, 1_CD mug_NN of_IN anti-CDK2_NN ,_, 1_CD mug_NN of_IN anti-p21_JJ ,_, 1_CD mug_NN of_IN anti-p27_JJ and_CC 1_CD mug_NN of_IN anti-p53_NN per_IN ml_NN in_IN TBST_NP containing_VBG 5_CD %_NN skim_NN milk_NN ._SENT Immunofluorescence_NN assay_NN ._SENT |_SYM Forty-eight_NP hours_NNS post-TPA_NN treatment_NN ,_, BCBL-1_NP cells_NNS were_VBD fixed_VBN with_IN 3.7_CD %_NN paraformaldehyde_NN in_IN PBS_NP for_IN 5_CD min_NN at_IN room_NN temperature_NN and_CC subsequently_RB treated_VBN with_IN 1.0_CD %_NN Triton_NP X-100_NP followed_VBD by_IN 1.0_CD %_NN NP-40_NP in_IN PBS_NP for_IN 10_CD min_NN each_DT at_IN room_NN temperature_NN ._SENT After_IN being_VBG washed_VBN twice_RB with_IN 0.2_CD %_NN Tween_NP 20_CD in_IN PBS_NP ,_, cells_NNS were_VBD smeared_VBN on_IN a_DT coverslip_NN (_( Fisher_NP )_) ._SENT After_IN being_VBG blocked_VBN with_IN PBS-2_JJ %_NN bovine_JJ serum_NN albumin_NN (_( Fisher_NP )_) ,_, cells_NNS were_VBD incubated_VBN with_IN anti-K-bZIP_NN rabbit_NN serum_NN (_( 1:2,000_CD )_) and_CC anti-CDK2_JJ mouse_NN monoclonal_NN antibody_NN (_( 5_CD mug/ml_NN ;_: B.D._NP Transduction_NP Labs_NP )_) in_IN PBS-2_JJ %_NN bovine_JJ serum_NN albumin_NN for_IN 1_CD h_NN at_IN room_NN temperature_NN ._SENT After_IN being_VBG washed_VBN four_CD times_NNS with_IN PBS_NP ,_, Alexa_NP Fluor_NP 555-conjugated_JJ goat_NN anti-rabbit_NN immunoglobulin_NN G_NP F(ab')2_NP (_( 1:3,000_NP )_) (_( Molecular_NP Probes_NP )_) and_CC Alexa_NP Fluor_NP 488-conjugated_JJ goat_NN anti-mouse_NN immunoglobulin_NN G_NP F(ab')2_NP (_( 1:2,000_NP )_) (_( Molecular_NP Probes_NP )_) in_IN PBS-2_JJ %_NN bovine_JJ serum_NN albumin_NN were_VBD applied_VBN as_IN secondary_JJ antibodies_NNS and_CC allowed_VBN to_TO react_VB for_IN 1_CD h_NN at_IN room_NN temperature_NN ._SENT DNA_NP was_VBD stained_VBN with_IN 1_CD muM_NN To-Pro3_NP (_( Molecular_NP Probes_NP )_) in_IN PBS_NP for_IN 1_CD min_NN at_IN room_NN temperature_NN ._SENT Imaging_NP was_VBD performed_VBN with_IN a_DT confocal_JJ microscope_NN equipped_VBN with_IN an_DT argon-krypton_NN laser_NN (_( LSM510-MicroSystem_NP ;_: Carl_NP Zeiss_NP Co._NP ,_, Ltd_NP )_) ._SENT Preparation_NN and_CC purification_NN of_IN GST_JJ fusion_NN proteins_NNS ._SENT |_SYM GST_JJ fusion_NN proteins_NNS were_VBD expressed_VBN in_IN Escherichia_NP coli_NNS strain_VBP BL21_NP transformed_VBD with_IN the_DT following_VBG plasmids_NNS encoding_VBG distinct_JJ domains_NNS of_IN K-bZIP_NP :_: pGEX-K-bZIP_NP F.L._NP (_( residues_NNS 1_CD to_TO 237_CD )_) ,_, pGEX-K-bZIP_NN I_PP (_( residues_NNS 1_CD to_TO 121_CD )_) ,_, pGEX-K-bZIP_NP II_NP (_( residues_NNS 107_CD to_TO 157_CD )_) ,_, pGEX-K-bZIP_NP III_NP (_( residues_NNS 122_CD to_TO 189_CD )_) ,_, pGEX_NP K-bZIP_NP IV_NP (_( residues_NNS 158_CD to_TO 208_CD )_) ,_, pGEX_JJ K-bZIP_NP V_CD (_( residues_NNS 190_CD to_TO 237_CD )_) ,_, or_CC pGEX4T-2_NN ._SENT The_DT GST_JJ fusion_NN proteins_NNS were_VBD then_RB purified_VBN with_IN glutathione-Sepharose_JJ beads_NNS (_( Amersham-Pharmacia_NP )_) by_IN a_DT standard_JJ procedure_NN ._SENT Bacterial_JJ cells_NNS (_( 500_CD ml_NN )_) were_VBD cultured_VBN in_IN Luria_NP broth_NN for_IN each_DT construct_NN ._SENT Protein_NN expression_NN was_VBD induced_VBN with_IN 1_CD mM_NNS (_( final_JJ concentration_NN )_) isopropyl-beta-d-thiogalactopyranoside_NN (_( IPTG_NP )_) ._SENT Bacterial_JJ cells_NNS were_VBD washed_VBN once_RB in_IN PBS_NP and_CC then_RB lysed_VBN by_IN sonication_NN in_IN PBS_NP containing_VBG 1_CD %_NN Triton_NP X-100_NP and_CC 1_CD %_NN Sarkosyl_NP ._SENT After_IN clearing_NN by_IN centrifugation_NN at_IN 7,000_CD x_NN g_NN for_IN 10_CD min_NN at_IN 4C_JJ ,_, glutathione-Sepharose_JJ beads_NNS (_( 500_CD mul_NN of_IN a_DT 1:1_CD slurry_NN in_IN PBS_NP )_) were_VBD added_VBN to_TO the_DT lysates_NNS for_IN affinity_NN purification_NN ._SENT After_IN incubation_NN overnight_JJ at_IN 4C_JJ with_IN rotation_NN ,_, the_DT beads_NNS were_VBD washed_VBN four_CD times_NNS in_IN PBS_NP containing_VBG 1_CD %_NN Triton_NP X-100_NP and_CC 1_CD %_NN Sarkosyl_NP ._SENT The_DT proteins_NNS immobilized_VBN on_IN the_DT glutathione-agarose_JJ beads_NNS were_VBD quantified_VBN by_IN Coomassie_NP blue_JJ staining_VBG ,_, with_IN bovine_JJ serum_NN albumin_NN as_IN a_DT protein_NN standard_NN ._SENT In_IN vitro_NN interaction_NN assay_NN ._SENT |_SYM GST-protein_NP beads_NNS containing_VBG approximately_RB 2.0_CD mug_NN of_IN proteins_NNS were_VBD resuspended_VBN in_IN binding_JJ buffer_NN (_( 20_CD mM_NP HEPES_NP [_SYM pH_NN 7.9_CD ]_SYM ,_, 150_CD mM_NP NaCl_NP ,_, 1_CD mM_NP EDTA_NP ,_, 4_CD mM_NP MgCl2_NP ,_, 1_CD mM_NP dithiothreitol_NN ,_, 0.1_CD %_NN NP-40_NN ,_, and_CC 10_CD %_NN glycerol_NN ,_, supplemented_VBN before_IN use_NN with_IN 1_CD mg_NN of_IN bovine_JJ serum_NN albumin_NN per_IN ml_NN ,_, 0.5_CD mM_NP phenylmethylsulfonyl_NN fluoride_NN ,_, and_CC 1_CD x_SYM protease_NN inhibitor_NN cocktail_NN )_) ,_, and_CC then_RB incubated_VBN for_IN 30_CD min_NN at_IN 4C_JJ with_IN 10_CD mul_NN of_IN in_IN vitro_NN translated_VBN proteins_NNS ,_, which_WDT were_VBD labeled_VBN with_IN [_SYM 35S]methionine_JJ with_IN the_DT TNT_NP coupled_VBN transcription_NN and_CC translation_NN system_NN (_( Promega_NP )_) ._SENT The_DT beads_NNS were_VBD washed_VBN four_CD times_NNS with_IN binding_JJ buffer_NN and_CC then_RB resuspended_VBN and_CC boiled_VBN in_IN 2x_NP SDS_NP sample_NN buffer_NN ._SENT After_IN proteins_NNS were_VBD separated_VBN by_IN SDS-PAGE_NP ,_, radiolabeled_JJ polypeptides_NNS retained_VBN on_IN the_DT beads_NNS were_VBD visualized_VBN by_IN autoradiography_NN ._SENT In_IN vitro_NN kinase_NN assay_NN ._SENT |_SYM cyclin-CDK2_NN complexes_NNS were_VBD immunoprecipitated_VBN from_IN 250_CD mug_NN of_IN total_JJ cell_NN lysate_NNS from_IN 293_CD stable_JJ cells_NNS ,_, BCBL-1_JJ cells_NNS ,_, or_CC HA-BCBL-1_JJ cells_NNS in_IN EBC_NP buffer_NN with_IN anti-CDK2_JJ antibody_NN (_( SC-163_NP ;_: Santa_NP Cruz_NP )_) ._SENT Immunocomplexes_NNS were_VBD washed_VBN three_CD times_NNS with_IN kinase_NN buffer_NN (_( 20_CD mM_NP HEPES_NP [_SYM pH_NN 7.5_CD ]_SYM ,_, 10_CD mM_NP MgCl2_NP ,_, 10_CD mM_NP MnCl2_NP ,_, 1_CD mM_NP dithiothreitol_NN ,_, 1_CD mM_NP NaF_NP ,_, 0.1_CD mM_NP Na2VO4_NP )_) ._SENT Kinase_NN reactions_NNS were_VBD performed_VBN for_IN 15_CD min_NN at_IN 30C_JJ with_IN histone_NN 1_CD (_( Upstate_NN )_) as_IN a_DT substrate_NN ._SENT In_IN vitro_NP CDK2_NP kinase_NN inhibition_NN assays_NNS were_VBD performed_VBN with_IN the_DT full-length_JJ GST_JJ fusion_NN with_IN K-bZIP_NP ._SENT The_DT full-length_JJ GST-K-bZIP_NP protein_NN was_VBD recovered_VBN from_IN bacterial_JJ lysates_NNS with_IN glutathione-Sepharose_JJ beads_NNS ,_, separated_VBN by_IN SDS-PAGE_NP ,_, excised_VBD ,_, equilibrated_VBN in_IN SDS_NP electrophoresis_NN buffer_NN ,_, and_CC electroeluted_VBD into_IN a_DT cellulose_NN tube_NN ._SENT The_DT purified_VBN protein_NN in_IN SDS_NP electrophoresis_NN buffer_NN was_VBD dialyzed_VBN against_IN PBS_NP overnight_RB ._SENT Then_RB 2_CD mul_NN of_IN CDK2-cyclin_NP A_NP (_( Upstate_NP )_) was_VBD incubated_VBN with_IN purified_VBN GST-K-bZIP_NN for_IN 1_CD h_NN at_IN 4C_JJ in_IN kinase_NN buffer_NN (_( 10_CD mul_NN of_IN kinase_NN buffer_NN and_CC 10_CD mul_NN of_IN PBS_NP containing_VBG 0.5_CD mug_NN of_IN purified_VBN GST-K-bZIP_NN as_RB indicated_VBD in_IN the_DT figure_NN legends_NNS )_) without_IN ATP_NP ._SENT Total_JJ protein_NN amounts_NNS were_VBD adjusted_VBN with_IN bovine_JJ serum_NN albumin_NN ._SENT Kinase_NN reactions_NNS were_VBD performed_VBN for_IN 5_CD min_NN at_IN 25C_JJ in_IN a_DT volume_NN of_IN 30_CD mul_NN (_( 20_CD mul_NN of_IN kinase_NN buffer_NN and_CC 10_CD mul_NN of_IN PBS_NP containing_VBG GST-K-bZIP_NP ,_, 10_CD muCi_NNS of_IN [_SYM gamma-32P]ATP_NN [_SYM Amersham-Pharmacia_NP ]_SYM ,_, 50_CD muM_NN cold_JJ ATP_NP ,_, and_CC 0.5_CD mug_NN of_IN histone_NN 1_CD as_IN a_DT substrate_NN )_) ._SENT Reactions_NNS were_VBD stopped_VBN by_IN addition_NN of_IN 30_CD mul_NN of_IN SDS_NP sample_NN buffer_NN ,_, and_CC the_DT mixtures_NNS were_VBD boiled_VBN ,_, fractionated_VBN by_IN SDS-PAGE_NP ,_, and_CC visualized_VBD with_IN a_DT phosphoimager_NN ._SENT Kinase_NN activity_NN was_VBD measured_VBN with_IN Quantity_NP One_CD software_NN (_( Bio-Rad_NP )_) ._SENT KSHV_NP lytic_JJ replication_NN prolongs_VBZ the_DT G1_JJ phase_NN of_IN naturally_RB infected_JJ B_NP cells_NNS ._SENT |_SYM In_IN our_PP$ investigation_NN of_IN TPA-induced_JJ reactivation_NN of_IN KSHV_NP ,_, we_PP observed_VBD a_DT general_JJ increase_NN in_IN G1_JJ phase_NN of_IN treated_VBN cells_NNS ._SENT These_DT results_NNS are_VBP illustrated_VBN in_IN Table_NP ._SENT KSHV_NP latent_JJ cell_NN lines_NNS BCP-1_NP and_CC BCBL-1_NP were_VBD used_VBN in_IN this_DT study_NN ,_, with_IN GA10_NP ,_, a_DT KSHV-free_NP B-cell_NN line_NN ,_, as_IN a_DT control_NN ._SENT We_PP measured_VBD the_DT fraction_NN of_IN cells_NNS in_IN G1_JJ phase_NN by_IN flow_NN cytometry_NN at_IN different_JJ times_NNS after_IN TPA_NP treatment_NN ._SENT TPA_NP treatment_NN of_IN BCP-1_NP resulted_VBD in_IN a_DT marked_JJ increase_NN in_IN the_DT G1_NP fraction_NN ,_, from_IN 47_CD %_NN before_IN treatment_NN to_TO 71_CD %_NN at_IN 48_CD h_NN after_IN treatment_NN ._SENT TPA_NP treatment_NN of_IN BCBL-1_NP cells_NNS had_VBD a_DT less_RBR robust_JJ effect_NN on_IN the_DT G1_NP fraction_NN ,_, from_IN 37_CD %_NN before_IN treatment_NN to_TO 46_CD %_NN at_IN 72_CD h_NN ,_, perhaps_RB reflecting_VBG the_DT fact_NN that_IN only_RB 10_CD to_TO 20_CD %_NN of_IN BCBL-1_JJ cells_NNS respond_VB to_TO TPA_NP treatment_NN ._SENT We_PP also_RB monitored_VBD the_DT molecular_JJ events_NNS of_IN BCP-1_JJ cells_NNS after_IN TPA_NP treatment_NN by_IN Western_JJ blot_NN analysis_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, there_EX was_VBD a_DT rapid_JJ rise_NN of_IN the_DT level_NN of_IN K-bZIP_NP within_IN 12_CD h_NN ,_, consistent_JJ with_IN its_PP$ classification_NN as_IN an_DT early-lytic_JJ gene_NN product_NN ._SENT This_DT was_VBD followed_VBN by_IN a_DT gradual_JJ rise_NN of_IN p21_JJ and_CC p27_JJ protein_NN levels_NNS ._SENT The_DT amount_NN of_IN p53_NN did_VBD not_RB seem_VB to_TO change_VB significantly_RB in_IN TPA-treated_NP BCP-1_NP ,_, likely_RB due_JJ to_TO the_DT high_JJ basal_JJ level_NN of_IN p53_NN in_IN these_DT cells_NNS ._SENT Thus_RB ,_, at_IN least_JJS for_IN this_DT cell_NN line_NN ,_, the_DT increase_NN in_IN p21_NN may_MD not_RB all_RB be_VB attributed_VBN to_TO p53_NN activation_NN ._SENT We_PP wished_VBD to_TO elucidate_VB the_DT mechanism_NN underlying_VBG the_DT cell_NN cycle_NN delay_NN and_CC hypothesized_VBD that_IN ,_, in_IN a_DT manner_NN similar_JJ to_TO EBV_NP Zta_NP ,_, KSHV_NP K-bZIP_NP may_MD play_VB a_DT role_NN in_IN this_DT process_NN ._SENT K-bZIP_NP physically_RB interacts_VBZ with_IN cyclin-CDK2_NN in_IN naturally_RB infected_JJ B_NP cells_NNS ._SENT |_SYM To_TO explore_VB the_DT possible_JJ role_NN of_IN K-bZIP_NP in_IN cell_NN cycle_NN regulation_NN ,_, we_PP asked_VBD whether_IN K-bZIP_NP interacts_VBZ directly_RB with_IN cell_NN cycle_NN regulators_NNS in_IN BCBL-1_JJ cells_NNS without_IN artificial_JJ overexpression_NN of_IN the_DT K-bZIP_NP gene_NN product_NN ._SENT To_TO this_DT end_NN ,_, BCBL-1_NP cells_NNS were_VBD treated_VBN with_IN TPA_NP to_TO induce_VB the_DT expression_NN of_IN K-bZIP_NP ,_, and_CC cell_NN extracts_VBZ isolated_VBN at_IN 48_CD h_NN after_IN treatment_NN were_VBD subjected_VBN to_TO immunoprecipitation-Western_JJ blot_NN analyses_NNS with_IN antibodies_NNS against_IN various_JJ CDKs_NNS ,_, cyclins_NNS ,_, and_CC additional_JJ unrelated_JJ molecules_NNS as_IN controls_NNS ._SENT Among_IN the_DT CDKs_NNS and_CC cyclins_NNS tested_VBD ,_, K-bZIP_NP only_RB coprecipitated_VBD with_IN CDK2_NP and_CC its_PP$ associated_JJ cyclins_NNS ,_, cyclins_NNS E_NP and_CC A_NP ,_, as_RB shown_VBN in_IN Fig._NN ._SENT This_DT is_VBZ interesting_JJ ,_, as_IN Polson_NP et_FW al._FW demonstrated_VBD that_IN K-bZIP_NP is_VBZ phosphorylated_JJ by_IN cyclin-CDK2_NN ._SENT p53_NN ,_, which_WDT is_VBZ also_RB known_VBN to_TO interact_VB with_IN K-bZIP_NP ,_, was_VBD used_VBN as_IN a_DT positive_JJ control_NN ,_, and_CC antibody_NN against_IN the_DT irrelevant_JJ epitope_NN HA_NP was_VBD used_VBN as_IN a_DT negative_JJ control_NN ._SENT To_TO further_RBR establish_VB the_DT interaction_NN between_IN K-bZIP_NP and_CC cyclin-CDK2_JJ in_IN vivo_RB ,_, we_PP studied_VBD their_PP$ subcellular_JJ colocalization_NN in_IN BCBL-1_JJ cells_NNS ._SENT For_IN this_DT experiment_NN ,_, we_PP used_VBD highly_RB specific_JJ mouse_NN monoclonal_NN antibodies_NNS against_IN CDK2_NP ,_, allowing_VBG them_PP to_TO be_VB distinguished_VBN from_IN the_DT rabbit_NN immunoglobulin_NN G_NN antibody_NN against_IN K-bZIP_NP ._SENT Alexa_NP Fluor_NP 555-conjugated_JJ anti-rabbit_NN immunoglobulin_NN G_NP and_CC Alexa_NP Fluor_NP 488-conjugated_JJ anti-mouse_NN immunoglobulin_NN G_NP were_VBD used_VBN to_TO detect_VB K-bZIP_NP (_( red_JJ )_) and_CC CDK2_NP (_( green_JJ )_) ,_, respectively_RB ._SENT As_IN shown_VBN in_IN Fig._NN ,_, K-bZIP_NP was_VBD localized_VBN in_IN the_DT nucleus_NN in_IN a_DT diffuse_JJ pattern_NN ,_, and_CC CDK2_NP was_VBD primarily_RB present_JJ in_IN Cajal_JJ bodies_NNS ,_, as_IN we_PP showed_VBD previously_RB ._SENT The_DT merged_JJ image_NN indicates_VBZ that_IN a_DT fraction_NN of_IN K-bZIP_NP and_CC CDK2_NP were_VBD colocalized_VBN in_IN the_DT Cajal_JJ bodies_NNS in_IN this_DT environment_NN ._SENT K-bZIP_NP interacts_VBZ with_IN CDK2_NP in_IN the_DT absence_NN of_IN other_JJ viral_JJ factors_NNS ._SENT |_SYM The_DT studies_NNS described_VBD above_IN were_VBD conducted_VBN in_IN physiologically_RB relevant_JJ KSHV-infected_NP BCBL-1_NP cells_NNS ._SENT However_RB ,_, the_DT situation_NN was_VBD complicated_VBN by_IN the_DT presence_NN of_IN other_JJ KSHV_NP gene_NN products_NNS in_IN these_DT cells_NNS ._SENT Additionally_RB ,_, to_TO rule_VB out_RP the_DT possibility_NN that_IN the_DT observed_JJ association_NN in_IN BCBL-1_NP cells_NNS was_VBD due_JJ to_TO nonspecific_JJ effects_NNS of_IN the_DT polyclonal_JJ antibodies_NNS used_VBN ,_, we_PP constructed_VBD CDK2_NP and_CC K-bZIP_NP expression_NN vectors_NNS tagged_VBN with_IN Flag_NP and_CC T7_JJ sequences_NNS ,_, respectively_RB ._SENT These_DT constructs_NNS were_VBD linked_VBN to_TO a_DT cytomegalovirus_NN promoter_NN and_CC cotransfected_JJ into_IN 293T_JJ cells_NNS ._SENT Forty-eight_NN hours_NNS after_IN transfection_NN ,_, the_DT cells_NNS were_VBD harvested_VBN and_CC lysed_VBN ._SENT CDK2_NP was_VBD immunoprecipitated_VBN with_IN Flag_NP antibody-coated_JJ beads_NNS ,_, and_CC the_DT coprecipitates_NNS were_VBD probed_VBN with_IN anti-T7_JJ antibody_NN to_TO detect_VB K-bZIP_NP ._SENT As_IN shown_VBN in_IN Fig._NN ,_, T7-K-bZIP_NP coprecipitated_VBD with_IN Flag-CDK2_NP but_CC not_RB with_IN the_DT Flag-tagged_JJ vector_NN control_NN ._SENT Reciprocal_JJ experiments_NNS with_IN the_DT T7-CDK2_NP and_CC Flag-K-bZIP_NP expression_NN vectors_NNS confirmed_VBD this_DT result_NN (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT data_NNS showed_VBD that_DT K-bZIP_NN without_IN other_JJ viral_JJ products_NNS is_VBZ able_JJ to_TO interact_VB with_IN CDK2_NP ._SENT K-bZIP_NP interacts_VBZ directly_RB with_IN cyclin-CDK2_NN via_IN the_DT basic_JJ region_NN and_CC downmodulates_VBZ CKD2_JJ kinase_NN activity_NN ._SENT |_SYM To_TO determine_VB whether_IN the_DT interaction_NN between_IN K-bZIP_NP and_CC cyclin-CDK2_NN is_VBZ direct_JJ ,_, we_PP incubated_VBD in_IN vitro-translated_NNS [_SYM 35S]CDK2_JJ ,_, cyclin_NP A_NP ,_, or_CC cyclin_NN E_NN with_IN purified_VBN GST-K-bZIP_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, full-length_JJ GST-K-bZIP_NN pulled_VBD down_RP CDK2_NP ,_, cyclin_NP A_NP ,_, and_CC cyclin_NP E._NP There_RB was_VBD some_DT background_NN association_NN of_IN GST_NP with_IN in_IN vitro-translated_JJ cyclins_NNS A_NP and_CC E_NP ,_, which_WDT however_RB could_MD be_VB distinguished_VBN from_IN the_DT increased_VBN intensities_NNS of_IN the_DT GST-K-bZIP_NP pulldowns_NNS ._SENT To_TO map_VB the_DT interaction_NN domain_NN of_IN K-bZIP_NP ,_, we_PP constructed_VBD a_DT series_NN of_IN K-bZIP_NP deletion_NN mutants_NNS (_( Fig._NN ,_, upper_JJ panel_NN )_) and_CC subjected_VBN them_PP to_TO the_DT GST_JJ pulldown_NN assay_NN ._SENT The_DT results_NNS in_IN Fig._NN ,_, lower_JJR panel_NN ,_, showed_VBD that_IN the_DT N-terminal_JJ half_NN of_IN K-bZIP_NP was_VBD ineffective_JJ in_IN pulling_VBG down_RP CDK2_NP ,_, cyclin_NP A_NP ,_, or_CC cyclin_NP E._NP By_IN contrast_NN ,_, the_DT basic_JJ region_NN appeared_VBD to_TO bind_VB CDK2_NP ,_, cyclin_NP A_NP ,_, and_CC cyclin_NN E_NN with_IN an_DT intensity_NN even_RB higher_JJR than_IN that_DT of_IN the_DT full-length_JJ K-bZIP_NN ._SENT The_DT leucine_NN zipper_NN region_NN showed_VBD limited_JJ affinity_NN toward_IN cyclin_NP A_NP and_CC CDK2_NP ._SENT These_DT data_NNS suggest_VBP that_IN the_DT interaction_NN between_IN K-bZIP_NP and_CC the_DT cyclin-CDK2_JJ complex_NN is_VBZ direct_JJ and_CC that_IN the_DT basic_JJ region_NN of_IN K-bZIP_NP is_VBZ the_DT primary_JJ domain_NN interacting_VBG with_IN this_DT complex_JJ ,_, consistent_JJ with_IN the_DT presence_NN of_IN a_DT cyclin-binding_JJ motif_NN in_IN this_DT region_NN (_( see_VB Discussion_NP )_) ._SENT This_DT direct_JJ interaction_NN has_VBZ a_DT functional_JJ impact_NN on_IN CDK2_NP ._SENT In_IN an_DT in_IN vitro_NP kinase_NN assay_NN of_IN the_DT CDK2_JJ complex_NN with_IN histone_NN 1_CD as_IN a_DT substrate_NN ,_, the_DT addition_NN of_IN GST-K-bZIP_NP significantly_RB reduced_VBD the_DT kinase_NN activity_NN (_( Fig._NN ,_, upper_JJ panel_NN )_) ._SENT The_DT lower_JJR panel_NN provides_VBZ the_DT proper_JJ reaction_NN control_NN ,_, which_WDT indicates_VBZ that_IN the_DT amounts_NNS of_IN histone_NN 1_CD were_VBD similar_JJ and_CC the_DT only_JJ difference_NN in_IN these_DT two_CD reactions_NNS was_VBD the_DT addition_NN of_IN purified_VBN GST-K-bZIP_NN ._SENT These_DT results_NNS suggest_VBP that_IN direct_JJ association_NN of_IN K-bZIP_NP with_IN the_DT cyclin-CDK2_JJ complex_NN leads_VBZ to_TO inhibition_NN of_IN the_DT kinase_NN activity_NN ._SENT K-bZIP_NN expression_NN affects_VBZ cell_NN growth_NN kinetics_NNS ._SENT |_SYM To_TO study_VB the_DT biological_JJ consequence_NN of_IN K-bZIP_NP interaction_NN with_IN cyclin-CDK2_NN ,_, we_PP established_VBD stable_JJ clones_NNS of_IN 293_CD cells_NNS bearing_VBG Flag-K-bZIP_NP ._SENT Cells_NNS transfected_VBN with_IN Flag-K-bZIPDeltaBR_NP ,_, a_DT mutant_JJ devoid_JJ of_IN the_DT basic_JJ region_NN ,_, were_VBD used_VBN as_IN controls_NNS ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT growth_NN rate_NN of_IN cells_NNS bearing_VBG wild-type_NP K-bZIP_NP (_( K-bZIP_NP #1_NP )_) was_VBD significantly_RB lower_JJR than_IN the_DT parental_JJ line_NN ._SENT An_DT independently_RB isolated_VBN K-bZIP-293_NP line_NN (_( K-bZIP_NP #2_NP )_) behaved_VBD similarly_RB ,_, suggesting_VBG that_IN the_DT results_NNS are_VBP not_RB due_JJ to_TO clonal_JJ variations_NNS of_IN selectants_NNS ._SENT 293_CD cells_NNS bearing_VBG a_DT mutation_NN that_WDT deletes_VBZ the_DT basic_JJ region_NN ,_, expected_VBN to_TO be_VB incapable_JJ of_IN interacting_VBG with_IN CDK2_NP ,_, grew_VBD with_IN kinetics_NNS nearly_RB identical_JJ to_TO that_DT of_IN the_DT parental_JJ 293_CD cells_NNS ._SENT In_IN cells_NNS expressing_VBG the_DT full-length_JJ construct_NN ,_, CDK2_NP activity_NN was_VBD barely_RB detectable_JJ ,_, as_RB shown_VBN in_IN Fig._NN ._SENT In_IN agreement_NN with_IN the_DT kinetics_NN data_NNS ,_, the_DT CDK2_NP activity_NN in_IN K-bZIPDeltaBR-transfected_NP cells_NNS remained_VBD similar_JJ to_TO that_DT of_IN vector-transfected_JJ cells_NNS ._SENT The_DT downmodulation_NN of_IN CDK2_NP was_VBD also_RB accompanied_VBN by_IN an_DT increase_NN in_IN the_DT levels_NNS of_IN p21_NN ._SENT It_PP has_VBZ been_VBN reported_VBN that_DT phosphorylation_NN by_IN CDK2_JJ targets_NNS p21_JJ for_IN degradation_NN ._SENT Inhibition_NN of_IN CDK2_JJ activity_NN by_IN K-bZIP_NP would_MD thus_RB be_VB expected_VBN to_TO increase_VB the_DT p21_JJ protein_NN level_NN ,_, as_IN we_PP observed_VBD here_RB ._SENT To_TO offer_VB an_DT independent_JJ confirmation_NN of_IN this_DT notion_NN ,_, HeLa_NP cells_NNS were_VBD transiently_RB transfected_VBN with_IN K-bZIP_NP ,_, and_CC the_DT levels_NNS of_IN p21_JJ protein_NN were_VBD measured_VBN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, K-bZIP_NP expression_NN led_VBD to_TO an_DT increased_VBN level_NN of_IN p21_NN ._SENT These_DT data_NNS suggest_VBP that_IN the_DT significant_JJ growth-inhibitory_JJ effect_NN of_IN K-bZIP_NP is_VBZ caused_VBN by_IN a_DT combined_JJ effect_NN of_IN binding_VBG of_IN K-bZIP_NP to_TO cyclin-CDK2_NN and_CC the_DT increased_VBN expression_NN of_IN CDK2_NP inhibitor_NN p21_NN ._SENT Recently_RB ,_, Wu_NP et_FW al._FW showed_VBD that_IN K-bZIP_NP enhanced_VBD p21_JJ expression_NN through_IN interaction_NN with_IN C/EBPalpha_NP ,_, a_DT transcriptional_JJ factor_NN for_IN the_DT p21_JJ locus_NN ._SENT These_DT authors_NNS mapped_VBD the_DT interacting_VBG domain_NN to_TO be_VB primarily_RB in_IN the_DT leucine_NN zipper_NN domain_NN of_IN K-bZIP_NP ._SENT To_TO distinguish_VB the_DT relative_JJ contributions_NNS of_IN p21_JJ increase_NN by_IN CDK2_NP and_CC C/EBPalpha_NP ,_, we_PP constructed_VBD a_DT K-bZIP_NP mutant_NN ,_, K-bZIPDeltaLZ_NP ,_, devoid_JJ of_IN the_DT leucine_NN zipper_NN region_NN (_( amino_NN acids_NNS 189_CD to_TO 237_CD )_) ,_, and_CC developed_VBD a_DT corresponding_JJ ,_, stable_JJ 293_CD clone_NN ._SENT K-bZIPDeltaLZ_NP bound_JJ cyclin-CDK2_NN but_CC failed_VBD to_TO interact_VB with_IN C/EBPalpha_NP (_( data_NN not_RB shown_VBN )_) ._SENT As_IN shown_VBN in_IN Fig._NN ,_, increased_VBD p21_JJ expression_NN was_VBD observed_VBN in_IN a_DT K-bZIPDeltaLZ_NP clone_NN ,_, albeit_IN at_IN a_DT lower_JJR level_NN ,_, compared_VBN to_TO the_DT wild-type_NN K-bZIP_NN clones_NNS ._SENT These_DT data_NNS suggest_VBP that_IN K-bZIP_NP mediated_VBD the_DT increase_NN in_IN p21_JJ expression_NN through_IN both_DT CDK2_NP and_CC other_JJ pathways_NNS ,_, such_JJ as_IN C/EBPalpha_NP ._SENT K-bZIP_NP overexpression_NN inhibits_VBZ growth_NN of_IN BCBL-1_NP and_CC extends_VBZ G1_JJ phase_NN of_IN reactivated_VBN cells_NNS ._SENT |_SYM Having_VBG demonstrated_VBN that_IN K-bZIP_NP expression_NN leads_VBZ to_TO growth_NN inhibition_NN of_IN 293_CD cells_NNS ,_, we_PP wished_VBD to_TO extend_VB this_DT analysis_NN to_TO the_DT more_RBR appropriate_JJ context_NN of_IN BCBL-1_JJ cells_NNS ._SENT BCBL-1_JJ cells_NNS were_VBD transfected_VBN with_IN HA-K-bZIP_NP ,_, which_WDT carries_VBZ the_DT G418_NP resistance_NN marker_NN gene_NN ._SENT Stable_JJ clones_NNS selected_VBN in_IN medium_NN supplemented_VBN with_IN G418_NP were_VBD pooled_VBN ,_, and_CC their_PP$ growth_NN rate_NN was_VBD compared_VBN to_TO that_DT of_IN vector-transfected_JJ BCBL-1_JJ cells_NNS which_WDT had_VBD been_VBN similarly_RB selected_VBN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT K-bZIP-BCBL-1_NP pool_NN displayed_VBD a_DT significantly_RB slower_JJR growth_NN rate_NN than_IN the_DT vector-transfected_JJ BCBL-1_JJ cells_NNS ._SENT This_DT slower_JJR growth_NN was_VBD accompanied_VBN by_IN much_RB reduced_VBN CDK2_NP kinase_NN activity_NN ,_, as_RB shown_VBN by_IN the_DT in_IN vitro_NP kinase_NN assay_NN ._SENT We_PP also_RB studied_VBD the_DT G1_JJ fraction_NN of_IN K-bZIP-BCBL-1_NP cells_NNS after_IN TPA_NP treatment_NN and_CC compared_VBN it_PP with_IN that_DT of_IN the_DT parental_JJ BCBL-1_JJ cells_NNS ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT constitutive_JJ expression_NN of_IN K-bZIP_NP increased_VBD the_DT fraction_NN of_IN cells_NNS in_IN G1_NP before_IN TPA_NP treatment_NN (_( 0_CD h_NN )_) to_TO 57_CD %_NN (_( from_IN the_DT original_JJ 37_CD %_NN in_IN parental_JJ BCBL-1_JJ cells_NNS ,_, Table_NP )_) ._SENT The_DT HA_NP epitope_NN tag_NN allowed_VBD us_PP to_TO distinguish_VB between_IN the_DT ectopic_JJ and_CC endogenous_JJ forms_NNS of_IN K-bZIP_NP by_IN size_NN ,_, and_CC their_PP$ levels_NNS through_IN the_DT course_NN of_IN TPA_NP treatment_NN are_VBP shown_VBN in_IN Fig._NN ._SENT Because_IN TPA_NP treatment_NN induces_VBZ the_DT expression_NN of_IN the_DT endogenous_JJ viral_JJ K-bZIP_NN ,_, we_PP would_MD expect_VB it_PP to_TO work_VB in_IN concert_NN with_IN the_DT ectopically_RB expressed_VBN HA-K-bZIP_NP to_TO further_RBR augment_VB the_DT G1_JJ fraction_NN increase_NN ._SENT Indeed_RB ,_, the_DT G0/G1_NP fraction_NN increased_VBD from_IN 54_CD %_NN at_IN 4_CD h_NN to_TO 63_CD %_NN at_IN 24_CD h_NN and_CC to_TO 80_CD %_NN at_IN 72_CD h_NN after_IN TPA_NP treatment_NN ._SENT At_IN the_DT same_JJ time_NN ,_, the_DT S_NP fraction_NN was_VBD reduced_VBN from_IN 27_CD %_NN at_IN 4_CD h_NN posttreatment_NN to_TO only_RB 7_CD %_NN at_IN 72_CD h._NN In_IN parallel_NN ,_, the_DT levels_NNS of_IN both_DT p21_JJ and_CC p27_JJ increased_VBD significantly_RB ._SENT This_DT showed_VBD that_IN a_DT combined_JJ action_NN of_IN exogenous_JJ and_CC endogenous_JJ K-bZIP_NP expression_NN has_VBZ a_DT devastating_JJ effect_NN on_IN the_DT cell_NN cycle_NN progression_NN of_IN the_DT infected_JJ cell_NN ._SENT Previously_RB ,_, we_PP and_CC others_NNS independently_RB reported_VBD the_DT identification_NN of_IN a_DT basic_JJ leucine_NN zipper_NN protein_NN of_IN KSHV_NP ,_, and_CC we_PP designated_VBD this_DT gene_NN K-bZIP_NN ._SENT K-bZIP_NP is_VBZ the_DT structural_JJ and_CC positional_JJ analogue_NN of_IN the_DT EBV_NP Zta_NP gene_NN ._SENT EBV_NP Zta_NP functions_NNS as_IN a_DT potent_JJ transcriptional_JJ factor_NN which_WDT triggers_VBZ lytic_JJ replication_NN when_WRB overexpressed_VBN in_IN latent_JJ EBV_NP cell_NN lines_NNS ,_, and_CC it_PP ,_, together_RB with_IN Rta_NP ,_, represents_VBZ the_DT main_JJ latent_JJ to_TO lytic_JJ replication_NN switch_NN for_IN the_DT virus_NN ._SENT There_EX is_VBZ considerable_JJ evidence_NN indicating_VBG that_IN KSHV_NP Rta_NP ,_, the_DT ortholog_NN of_IN EBV_NP Rta_NP ,_, is_VBZ a_DT potent_JJ activator_NN of_IN KSHV_NP replication_NN ._SENT Overexpression_NN of_IN KSHV_NP Rta_NP in_IN the_DT BCBL-1_NP cell_NN line_NN leads_VBZ to_TO reactivation_NN of_IN the_DT latent_JJ KSHV_NP genome_NN ._SENT In_IN contrast_NN ,_, overexpression_NN of_IN K-bZIP_NP has_VBZ not_RB yielded_VBN lytic_JJ replication_NN and_CC ,_, as_IN shown_VBN in_IN this_DT report_NN ,_, it_PP results_VBZ in_IN a_DT reduction_NN of_IN the_DT growth_NN rate_NN in_IN the_DT latent_JJ cells_NNS ._SENT We_PP recently_RB reported_VBD that_IN K-bZIP_NP is_VBZ a_DT transcriptional_JJ coregulator_NN of_IN KSHV_NP Rta_NP ._SENT Through_IN association_NN ,_, K-bZIP_NP suppresses_VBZ the_DT transactivation_NN ability_NN of_IN KSHV_NP Rta_NP in_IN a_DT promoter-dependent_JJ manner_NN ._SENT Others_NNS have_VBP shown_VBN that_IN K-bZIP_NP is_VBZ a_DT coregulator_NN of_IN CBP_NP ,_, p53_CD ,_, and_CC C/EBPalpha_NP ._SENT Thus_RB ,_, K-bZIP_NP 's_POS transcriptional_JJ role_NN seems_VBZ at_IN present_JJ to_TO be_VB limited_VBN to_TO its_PP$ activity_NN as_IN a_DT coactivator_NN or_CC a_DT corepressor_NN ._SENT By_IN analogy_NN to_TO EBV_NP Zta_NP ,_, K-bZIP_NP may_MD have_VB other_JJ nontranscriptional_JJ functions_NNS in_IN the_DT KSHV_NP life_NN cycle_NN ._SENT EBV_NP Zta_NP is_VBZ known_VBN to_TO bind_VB the_DT viral_JJ DNA_NN replication_NN origin_NN and_CC is_VBZ involved_VBN in_IN EBV_NP genomic_JJ replication_NN ._SENT K-bZIP_NN was_VBD similarly_RB shown_VBN to_TO assist_VB in_IN the_DT formation_NN of_IN a_DT potential_JJ KSHV_NP DNA_NP prereplication_NN complex_NN ,_, though_IN its_PP$ specific_JJ role_NN in_IN genome_NN replication_NN remains_VBZ elusive_JJ ._SENT EBV_NP Zta_NP has_VBZ also_RB been_VBN shown_VBN to_TO mediate_VB cellular_JJ growth_NN arrest_NN by_IN stabilizing_VBG p53_NN ,_, inducing_VBG the_DT expression_NN of_IN p21_JJ and_CC p27_JJ ,_, thereby_RB contributing_VBG to_TO the_DT inhibition_NN of_IN CDK2_NP activity_NN ._SENT In_IN this_DT study_NN ,_, we_PP explored_VBD the_DT role_NN of_IN K-bZIP_NP in_IN modulating_VBG cell_NN cycle_NN progression_NN ._SENT CDK2_NP plays_VBZ a_DT pivotal_JJ role_NN in_IN cell_NN cycle_NN progression_NN ._SENT Phosphorylation_NN by_IN CDK2_NP of_IN retinoblastoma_NN protein_NN or_CC its_PP$ related_JJ molecules_NNS ,_, the_DT p130_NN and_CC p107_JJ pocket_NN proteins_NNS ,_, sets_VBZ the_DT stage_NN for_IN entry_NN into_IN the_DT S_NP phase_NN by_IN releasing_VBG and_CC activating_VBG E2F_NP ,_, a_DT transactivator_NN of_IN cyclin_NN E_NN and_CC DNA_NN polymerase_NN ._SENT This_DT is_VBZ viewed_VBN as_IN a_DT major_JJ pathway_NN by_IN which_WDT CDK2_NP advances_NNS G1_NP to_TO S_NP transition_NN ._SENT Recently_RB ,_, it_PP was_VBD shown_VBN that_IN CDK2_NP has_VBZ additional_JJ substrates_NNS which_WDT facilitate_VBP this_DT transition_NN in_IN a_DT retinoblastoma_NN protein-independent_NN manner_NN ._SENT These_DT substrates_NNS include_VBP E2F1_NP ,_, E2F5_NP ,_, histone_NN H1_NP ,_, HIRA_NP ,_, and_CC NPAT_NP ._SENT HIRA_NP and_CC NPAT_NP are_VBP both_CC involved_VBN in_IN the_DT histone_NN biosynthesis_NN which_WDT accompanies_VBZ DNA_NN replication_NN ._SENT CDK2_NP also_RB phosphorylates_VBZ its_PP$ own_JJ inhibitors_NNS ,_, p21_JJ and_CC p27_JJ ,_, targeting_VBG them_PP for_IN degradation_NN ._SENT Thus_RB ,_, CDK2_NP activity_NN controls_VBZ multiple_JJ pathways_NNS leading_VBG to_TO S-phase_NP progression_NN ._SENT It_PP is_VBZ therefore_RB no_DT surprise_NN that_IN multiple_JJ signal_NN transduction_NN pathways_NNS such_JJ as_IN growth_NN factors_NNS ,_, oncogenes_NNS ,_, and_CC DNA_NP repair_NN machinery_NN all_DT target_NN CDK2_JJ activity_NN to_TO control_VB cell_NN cycle_NN ._SENT Viruses_NNS have_VBP also_RB evolved_VBN ways_NNS to_TO target_VB cyclin-CDK2_NN to_TO modulate_VB the_DT cell_NN cycle_NN to_TO suit_VB their_PP$ particular_JJ needs_NNS during_IN replication_NN ._SENT Some_DT of_IN these_DT viral_JJ gene_NN products_NNS ,_, primarily_RB those_DT involved_VBN in_IN latency_NN or_CC transformation_NN ,_, accelerate_VB G1_NP to_TO S_NP transition_NN ,_, while_IN others_NNS do_VBP the_DT opposite_NN ._SENT A_DT number_NN of_IN factors_NNS interact_VBP directly_RB with_IN cell_NN cycle_NN regulators_NNS such_JJ as_IN CDKs_NNS and_CC cyclins_NNS or_CC interact_VB with_IN checkpoint_NN proteins_NNS such_JJ as_IN the_DT CDK_NP inhibitors_NNS p53_NN and_CC retinoblastoma_NN protein_NN ;_: others_NNS transcriptionally_RB modulate_VBP CDK_NP inhibitors_NNS ._SENT There_EX are_VBP yet_RB other_JJ viral_JJ gene_NN products_NNS ,_, such_JJ as_IN v-cyclin_NN of_IN KSHV_NP ,_, which_WDT represent_VBP hyperactive_JJ homologs_NNS of_IN the_DT cell_NN cycle_NN proteins_VBZ themselves_PP ._SENT The_DT consequences_NNS of_IN all_PDT these_DT interactions_NNS are_VBP either_DT activation_NN or_CC inactivation_NN of_IN the_DT cyclin-CDK_NN complexes_NNS ,_, which_WDT leads_VBZ to_TO acceleration_NN or_CC deceleration_NN of_IN progression_NN through_IN the_DT cell_NN cycle_NN ._SENT In_IN this_DT report_NN ,_, we_PP have_VBP shown_VBN that_IN KSHV_NP K-bZIP_NP targets_VBZ CDK2_NP directly_RB and_CC induces_VBZ growth_NN delay_NN at_IN the_DT G0/G1_JJ phase_NN ._SENT K-bZIP_NP achieves_VBZ this_DT end_NN by_IN physically_RB associating_VBG via_IN its_PP$ basic_JJ region_NN with_IN cyclin-CDK2_NN ._SENT This_DT interaction_NN is_VBZ direct_JJ ,_, as_RB demonstrated_VBN by_IN in_IN vitro_NN studies_NNS with_IN purified_VBN protein_NN preparations_NNS ,_, and_CC can_MD be_VB detected_VBN in_IN naturally_RB infected_JJ B_NP cells_NNS without_IN overexpression_NN of_IN either_DT component_NN ._SENT In_IN addition_NN ,_, some_DT of_IN the_DT K-bZIP_NP and_CC CDK2_NP are_VBP found_VBN to_TO be_VB colocalized_VBN in_IN the_DT nucleus_NN ._SENT The_DT consequence_NN of_IN this_DT interaction_NN is_VBZ the_DT inhibition_NN of_IN CDK2_NP kinase_NN activity_NN ._SENT 